Locations:
Min Investment:
Max Investment:
Target Investment:
2023
We back Seed, Series A, and Series B digital health, tech-enabled services, and medical device companies around the world that maximize direct life-saving impact.
2021 - 2023
2021 - 2023
Focus on Seed and Series A investments in health technology, tech-enabled healthcare services, and diagnostics companies. Companies I work with: - eBlu Solutions: Benefits verification & prior authorization for specialty medication - Biotia: AI-driven solutions to diagnose and control infectious diseases - HealtheMed: Clinic at home for Medicaid special needs population - Amplified Sciences: Diagnostics platform for accurate detection of cancers - iPill: Smart dispenser & companion app for improving prescription adherence and reducing opioid abuse - Rhythm Science: Integrated software platform for cardiac data management across hypertension, heart failure, and rhythm disorders - Atalan Tech: Applying machine learning to predict and prevent clinician burnout and turnover at health systems
2020 - 2021
2020 - 2021
2020 - 2021
2020 - 2021
At Genentech / Roche, I was part of the Center of Financial Insights (CoFI) driving commercial insights across our therapeutic portfolio for global affiliates.
2019 - 2020
2019 - 2020
2019 - 2019
2019 - 2019
‘87 is the venture arm of Sterling Partners, a multi-strategy investment firm. ‘87 incubates direct to consumer startups through funding, technology, talent, content development, and infrastructure.
2014 - 2018
2016 - 2018
2015 - 2016
2014 - 2015